The U.S. Court of Appeals for the Third Circuit last week reversed a lower court, re-opening multidistrict litigation alleging Merck & Co. Inc., of Kenilworth, N.J., failed to add an adequate warning of the risk of thigh fractures to the labeling for its osteoporosis drug Fosamax (alendronate).